Vanda Pharmaceuticals (VNDA) Competitors $4.74 -0.05 (-1.04%) Closing price 04:00 PM EasternExtended Trading$4.74 0.00 (0.00%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VNDA vs. OPK, GERN, ZBIO, RGLS, LXRX, MYGN, EBS, RIGL, XOMA, and VSTMShould you be buying Vanda Pharmaceuticals stock or one of its competitors? The main competitors of Vanda Pharmaceuticals include OPKO Health (OPK), Geron (GERN), Zenas BioPharma (ZBIO), Regulus Therapeutics (RGLS), Lexicon Pharmaceuticals (LXRX), Myriad Genetics (MYGN), Emergent Biosolutions (EBS), Rigel Pharmaceuticals (RIGL), XOMA Royalty (XOMA), and Verastem (VSTM). These companies are all part of the "biotechnology" industry. Vanda Pharmaceuticals vs. Its Competitors OPKO Health Geron Zenas BioPharma Regulus Therapeutics Lexicon Pharmaceuticals Myriad Genetics Emergent Biosolutions Rigel Pharmaceuticals XOMA Royalty Verastem OPKO Health (NASDAQ:OPK) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations. Which has better earnings and valuation, OPK or VNDA? Vanda Pharmaceuticals has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOPKO Health$713.10M1.52-$53.22M-$0.07-19.57Vanda Pharmaceuticals$198.77M1.41-$18.90M-$0.75-6.32 Does the media favor OPK or VNDA? In the previous week, Vanda Pharmaceuticals had 2 more articles in the media than OPKO Health. MarketBeat recorded 4 mentions for Vanda Pharmaceuticals and 2 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.93 beat Vanda Pharmaceuticals' score of 0.47 indicating that OPKO Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OPKO Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vanda Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is OPK or VNDA more profitable? OPKO Health has a net margin of -5.66% compared to Vanda Pharmaceuticals' net margin of -21.98%. OPKO Health's return on equity of -2.85% beat Vanda Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets OPKO Health-5.66% -2.85% -1.82% Vanda Pharmaceuticals -21.98%-8.30%-6.85% Do institutionals & insiders believe in OPK or VNDA? 64.6% of OPKO Health shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 49.7% of OPKO Health shares are held by insiders. Comparatively, 10.0% of Vanda Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, OPK or VNDA? OPKO Health has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Do analysts rate OPK or VNDA? OPKO Health currently has a consensus target price of $2.75, suggesting a potential upside of 100.73%. Vanda Pharmaceuticals has a consensus target price of $16.50, suggesting a potential upside of 248.10%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than OPKO Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OPKO Health 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00Vanda Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 SummaryOPKO Health beats Vanda Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Vanda Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VNDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VNDA vs. The Competition Export to ExcelMetricVanda PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$282.30M$3.07B$5.70B$9.51BDividend YieldN/A2.36%4.69%4.01%P/E Ratio-6.3221.0428.0720.05Price / Sales1.41284.46448.5799.42Price / CashN/A42.7636.2258.56Price / Book0.518.378.665.87Net Income-$18.90M-$55.19M$3.25B$258.55M7 Day Performance-0.84%5.89%4.20%2.23%1 Month Performance2.82%17.63%10.82%12.76%1 Year Performance-22.93%5.09%34.70%19.36% Vanda Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VNDAVanda Pharmaceuticals4.7395 of 5 stars$4.74-1.0%$16.50+248.1%-22.4%$282.30M$198.77M-6.32290Upcoming EarningsOPKOPKO Health3.8825 of 5 stars$1.40+3.7%$2.75+96.4%-1.4%$1.07B$713.10M-20.002,997Positive NewsGERNGeron3.3916 of 5 stars$1.23-0.8%$4.61+274.9%-70.2%$789.78M$76.99M-5.8670Analyst RevisionZBIOZenas BioPharma1.7332 of 5 stars$14.29+4.1%$36.67+156.6%N/A$574.38M$5M0.00N/ANews CoverageRGLSRegulus Therapeutics1.6496 of 5 stars$8.16flat$8.50+4.2%N/A$564.92MN/A-11.1830LXRXLexicon Pharmaceuticals2.4823 of 5 stars$1.23flat$3.67+198.1%-47.9%$444.64M$31.08M0.00140MYGNMyriad Genetics4.5597 of 5 stars$4.45-0.4%$14.38+223.2%-83.4%$412.03M$837.60M0.002,700News CoverageEBSEmergent Biosolutions4.3363 of 5 stars$6.93+0.0%$14.33+106.8%-45.8%$376.14M$1.04B-2.562,420News CoveragePositive NewsRIGLRigel Pharmaceuticals3.202 of 5 stars$19.59+4.2%$36.40+85.8%+94.0%$336M$179.28M9.08160Positive NewsXOMAXOMA Royalty4.0741 of 5 stars$25.48-0.7%$69.50+172.8%-8.6%$307.19M$28.49M0.0010VSTMVerastem3.4967 of 5 stars$5.10-1.2%$13.38+162.3%+78.7%$283.54M$10K0.0050 Related Companies and Tools Related Companies OPKO Health Competitors Geron Competitors Zenas BioPharma Competitors Regulus Therapeutics Competitors Lexicon Pharmaceuticals Competitors Myriad Genetics Competitors Emergent Biosolutions Competitors Rigel Pharmaceuticals Competitors XOMA Royalty Competitors Verastem Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VNDA) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VNDA Stock Alerts